Literature DB >> 28775593

TRANSFUSION REACTIONS: AFMC EXPERIENCE.

Y V Machave1, P S Dhot2.   

Abstract

Transfusions of blood and its components are useful and lifesaving. Adverse effects occur during or after transfusion, called hazards or complications of blood transfusion. Complications/hazards of various types which occurred in the patients following transfusion of blood/blood components in Armed Forces Hospitals of Pune-Kirkee complex were analysed with relevant investigations. Out of a total number of 13,039 transfusions of blood and blood components from 01 June 1995 to 31 July 1997, there were 104 (0.8%) adverse reactions. Non haemolytic febrile transfusion reaction was the commonest seen in 73 (70.2%) transfusions, followed by allergic reactions in 19 (18.3%) cases. Nonspecific reactions were seen in 11 (10.6%). One haemolytic transfusion reaction occurred due to wrong labelling of blood sample received from the ward for compatibility testing. There were no fatalities.

Entities:  

Keywords:  Blood transfusion; Complication; Febrile reaction

Year:  2017        PMID: 28775593      PMCID: PMC5531794          DOI: 10.1016/S0377-1237(17)30258-7

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  4 in total

Review 1.  Role of leukocyte depletion in the prevention of transfusion-induced cytomegalovirus infection.

Authors:  G Andreu
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

2.  The influence of leukocyte and thrombocyte incompatibility on non-haemolytic transfusion reactions. I. A retrospective study.

Authors:  H Thulstrup
Journal:  Vox Sang       Date:  1971-09       Impact factor: 2.144

3.  Serological investigations of 1,358 transfusion reactions in 74,000 transfusions.

Authors:  S Ahrons; F Kissmeyer-Nielsen
Journal:  Dan Med Bull       Date:  1968-11

4.  Hemolytic transfusion reaction. Recent experience in a large blood bank.

Authors:  A A Pineda; S M Brzica; H F Taswell
Journal:  Mayo Clin Proc       Date:  1978-06       Impact factor: 7.616

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.